Precautions to improve the accuracy of quantitative determinations of biomarkers in clinical diagnostics.
Although protein biomarkers have a great potential as biomarkers for diagnosis of diseases, they are seldom used in hospitals. There are many reasons for this, for instance, the difficulties to (i) find a biomarker for which the concentration in body fluids clearly differs between patients and healthy subjects, (ii) attain purification of the biomarker close to 100%, which is required for production of conventional protein antibodies as well as artificial gel antibodies for selective capture of a biomarker, (iii) design a standard curve for rapid and accurate determination of the concentration of the biomarker in the body fluid because of adsorption of the biomarker onto vials, pipettes, etc., (iv) determine accurately the sample volume delivered by a pipette, (v) avoid polymerization of the biomarker upon storage and to decide whether it is in the form not only of monomers, but also of dimers, trimers, etc., in the native state, (vi) determine the degree of possible glycosylation and amidation of the biomarker and (vii) decide whether glycosylation and amidation positively or negatively affects the possibility to use the protein as a biomarker. In this article, we discuss in quantitative terms the difficulties (iii-vii) and how to overcome them, which also may help to overcome the difficulty (ii), which in turn minimizes difficulty (i).
Ghasemzadeh
Nasim
N
Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Wilhelmsen
Tore W
TW
Nyberg
Fred
F
Hjertèn
Stellan
S
D000906:Antibodies; D015415:Biomarkers / Q000032:analysis*; D001826:Body Fluids / Q000737:chemistry / Q000378:metabolism; D004591:Electrophoresis, Polyacrylamide Gel; D005782:Gels; D006031:Glycosylation; D013006:Growth Hormone / Q000032:analysis*; D006801:Humans; D012044:Regression Analysis; D015203:Reproducibility of Results
D000906:Antibodies; D015415:Biomarkers; D005782:Gels; D013006:Growth Hormone